STOCK TITAN

Acasti Pharma Inc - ACST STOCK NEWS

Welcome to our dedicated news page for Acasti Pharma (Ticker: ACST), a resource for investors and traders seeking the latest updates and insights on Acasti Pharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Acasti Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Acasti Pharma's position in the market.

Rhea-AI Summary
Acasti Pharma Inc. announced an extended cash runway into Q2 2026, well beyond the potential NDA submission for GTX-104 in 1H 2025. Patient enrollment for the pivotal STRIVE-ON Phase 3 trial continues as planned. Financially, the company reported a net loss of $2.4 million for Q3 2024, decreased from $3.9 million in Q3 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.53%
Tags
-
Rhea-AI Summary
Acasti Pharma Inc. (ACST) announces that its pivotal Phase 3 STRIVE-ON safety trial has been accepted for presentation at the 2024 International Stroke Conference. The trial focuses on the safety and tolerability of GTX-104, a novel formulation of nimodipine, in patients with aneurysmal subarachnoid hemorrhage (aSAH). The trial design includes approximately 100 patients enrolled at 25 hospitals in the U.S., with the primary endpoint being comparative adverse events, including hypotension, between patients administered GTX-104 and oral nimodipine. The results will be presented at the conference on February 8th.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.21%
Tags
none
-
Rhea-AI Summary
Acasti Pharma Inc. (Nasdaq: ACST) announced CEO Prashant Kohli's participation in investor and industry networking events in San Francisco to present GTX-104, the novel intravenous formulation of nimodipine for aSAH treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.85%
Tags
conferences
Rhea-AI Summary
Acasti Pharma Inc. (Nasdaq: ACST) announced the dosing of the first patient in the STRIVE-ON Phase 3 trial for GTX-104, secured $7.5 million in private placement equity financing, and presented positive results on the potential of GTX-104 as a new treatment standard for aSAH. The company also shared financial results for the quarter ended September 30, 2023, highlighting a net loss of $3.3 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.15%
Tags
-
Rhea-AI Summary
Acasti Pharma announces enrollment milestone in Phase 3 STRIVE-ON safety trial for GTX-104
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.65%
Tags
none
-
Rhea-AI Summary
Acasti Pharma Inc. will host a virtual KOL event titled GTX-104: a potential new treatment standard for rare and life-threatening aSAH on October 11, 2023. The event will feature discussions on the high unmet medical need and current treatment landscape for aSAH patients. Acasti's lead clinical asset, GTX-104, a novel formulation of nimodipine, is currently in Phase 3 targeting aSAH as an intravenous infusion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.63%
Tags
conferences
Rhea-AI Summary
Acasti Pharma Inc. has closed a private placement, raising approximately $7.5 million. The funds will be used for clinical trial expenses and other corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
35.39%
Tags
none
-
Rhea-AI Summary
Acasti Pharma to present at H.C. Wainwright Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.91%
Tags
conferences
-
Rhea-AI Summary
Acasti Pharma Inc. (Nasdaq: ACST) announced financial results and business highlights for the quarter ended June 30, 2023, emphasizing the progress in executing the strategic vision for the development of GTX-104. The company is focused on the Pivotal STRIVE-ON Phase 3 Safety Trial for GTX-104, with the first patient expected to be dosed prior to the end of 2023. Cash and cash equivalents were $21.6 million, projected to fund the clinical development of GTX-104 until Q2 2025. Additionally, the company's pharmacokinetic comparison of GTX-104 with oral nimodipine was accepted for presentation at the 2023 Neurocritical Care Society (NCS) annual meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.41%
Tags
conferences
Acasti Pharma Inc

Nasdaq:ACST

ACST Rankings

ACST Stock Data

31.49M
6.29M
16.02%
12.13%
0.02%
Medicinal and Botanical Manufacturing
Manufacturing
Link
Canada
Laval

About ACST

acasti pharma, inc., a subsiduary of neptune technologies & bioressources, is a quebec-based biopharmaceutical dedicated in advancing a proprietary portfolio based on marine phospholipids. our products can be used in prescription, medical food and over-the-counter applications, either as a stand-alone, or, as a fixed-dose combination to exisitng productrs, for the prevention and treatment of cardiometabolic disorders.